IL5 and eosinophilic esophagitis: The fact that symptom improvement in patients with EoE has been observed in clinical trials of dupilumab,208,209 but not with other biologics (such as IL-5 and sialic acid–binding immunoglobulin-like lectin 8 [Siglec-8] inhibitors),203–205 provides insight into neuroimmune factors that are particularly relevant to EoE symptoms.